- Display 15 Products per page
Outsourcing in Drug Development – The Contract Research Market from Preclinical to Phase III
Published: January 1, 2004 | Price: $3,500.00 – $7,000.00
The cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research. Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. This industry has evolved from providing limited clinical trial services...
Emerging Cancer Vaccine Market, The
Published: February 1, 2004 | Price: $3,500.00 – $7,000.00
Immunologic approaches to cancer therapy are not only increasing in reputation and number, but the market for these products is increasingly becoming a reality. Vaccines are in the forefront of this approach to cancer, and the handful of cancer vaccine products currently on the market for bladder, colon, and skin cancer are soon to be joined by many more with indications for more wide-spread forms, including lung, breast, ovarian, prostate, leukemia, and others. This new study from Kalorama discusses the...
Worldwide Market for Prescription Dermatological Drugs – 4th Edition, The
Published: February 1, 2004 | Price: $3,500.00 – $7,000.00
This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fourth time Kalorama Information has comprehensively studied the dermatology markets. For this latest edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of interviews with users of...
U.S. Market for OTC Diet Aids, The
Published: February 1, 2004 | Price: $3,000.00 – $6,000.00
Diet Aids are among the most rapidly growing categories of over-the-counter (OTC) products. Between 1998 and 2003, growth was driven by two main factors: changes in laws and lawsuits relating to the industry, and changes in consumer attitudes toward weight loss. Because both of these factors are subject to rapid and unpredictable shifts, the diet aids category remains a highly volatile market. The consumer attitude towards OTC diet aids has shown extreme changes during the last couple of years. While...
The Worldwide Market For Dialysis Equipment, Supplies, and Services
Published: March 1, 2004 | Price: $3,500.00 – $7,000.00
The dialysis industry enjoys a unique space in healthcare sector. The industry has its feet spread across the two most lucrative segments of the sector viz. medical devices industry (dialysis products and supplies segment) and healthcare services industry (dialysis services segment). Needless to say, the dialysis industry remains a robust, nearly $50 billion global industry that has managed to fuel its growth engine with a modest, but respectable 6% to 7% rise growth rate in the past 5 years. The...
Cardiovascular Disease: The 45 Market in the United States for Drugs and Medical Devices
Published: March 1, 2004 | Price: $2,995.00 – $5,990.00
Cardiovascular disease includes chronic conditions such as hypertension, congestive heart failure and atherosclerosis, as well as such acute conditions as myocardial infarction and cardiac arrest. While cardiovascular disease may be diagnosed at any age, it is most prevalent in later years, particularly among sedentary individuals who are also overweight or obese. With the aging of the "Baby Boom" generation, a generation that has defined the term "couch potato" and has grown up on and maintained a diet of fast-food, the...
Trends in Cell Therapeutics: Promise and Reality
Published: March 1, 2004 | Price: $3,500.00 – $7,000.00
Cell and tissue therapies are about to revolutionize the treatment of a number of diseases, including: organ, replacement, cartilage, skin, autoimmune diseases, diabetes, neurodegenerative diseases, cancer and cardiovascular tissue damage. Although cell therapy is not a new phenomenon, what is new is the scope and versatility of research using stem cell and tissue therapeutics, and products based on combinations of cell therapy, gene manipulation, and tissue engineering. The report provides world market projections 2002-2007, discusses market trends and issues including...
Growth Factor Inhibitors: Markets and Opportunities for a Growing Pipeline
Published: March 1, 2004 | Price: $3,500.00 – $7,000.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or blocks the ability of cells to divide and multiply. Blood and tissue growth factors have become exciting targets for compounds intended to inhibit or slow the mechanisms involved in their function or growth. This report highlights the research into, and the current and potential key world markets for, products that...
Medicare Reform and the Pharmaceutical Industry: Implications of the Medicare Prescription Drug Improvement and Modernization Act of 2003
Published: March 1, 2004 | Price: $795.00 – $1,590.00
The hard-fought battle over Medicare's prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts. This market briefing from Kalorama describes and assesses the provisions of the "Medicare Prescription Drug, Improvement and Modernization Act of 2003" and predicts...
Diagnostics for Emerging Infectious Disease Threats, Volumes I – III
Published: March 1, 2004 | Price: $3,995.00 – $7,990.00
A host of new and old infectious diseases have emerged on the world stage, presenting familiar and novel challenges to public health officials. New strains of once controlled bacteria, new immunocomprimised patient populations, and new bioterror threats have spurred diagnostics companies to develop new tests and kits to meet the demand. Kalorama has assembled the vital data developers and marketers need to understand the competitive and commercial landscape in three volumes: Prion Disease; Viral Disease ; and Baterial & Protozoal...
Diagnostics for Emerging Infectious Disease Threats Volume III: Bacterial Disease
Published: April 1, 2004 | Price: $1,995.00 – $3,990.00
The recent terrorism events, in addition to the ease of travel that allows infectious diseases to spread, and technology developments drive the renewed interest in clinical and environmental infectious disease diagnostics. The combined public health and bio-terrorism markets of several bacterial and protozoan diseases are estimated to be nearly $100 million. This report, the final volume of the Diagnostics for Emerging Infectious Disease Threats series, focuses on diagnostic testing for 11 bacterial and protozoal diseases in clinical and environmental testing:...
The U.S. Market for Interventional Radiology Products
Published: April 1, 2004 | Price: $3,500.00 – $7,000.00
Changing demographics are spurring dynamic growth in the interventional radiology market. The angioplasty balloon, coronary stent, vascular closure, and other associated equipment markets will experience healthy growth over the next 5 years. Persons over the age of 65 will be a major segment of the population in coming years. Chronic diseases and unhealthy habits such as smoking, lack of exercise, and poor diet are resulting in an epidemic of obesity and concomitant cardiac conditions. These factors and others will drive...
U.S. Market for Molecular Diagnostics, 2nd Edition
Published: May 1, 2004 | Price: $3,500.00 – $7,000.00
Molecular diagnostics are seen as being a major breakthrough in medical science. While the technology itself has broad applications to such areas as agricultural bioterrorism and environmental science, medical and medical research applications have provided the primary focus. As a result, great things have been predicted for the development and use of new therapeutics based on molecular testing approaches. The primary molecular diagnostics approaches are based on two major database sciences (genomics and proteomics) and their relationship to disease and...
Early Stage Drug Discovery 2004: Combi-chem & High Throughput Screening Revisited
Published: June 1, 2004 | Price: $2,995.00 – $5,990.00
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...
Market for Generic Biologics: Issues, Trends, and Market Potential, The
Published: June 1, 2004 | Price: $1,500.00 – $3,000.00
Biologics, or biopharmaceuticals, are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biogenerics are not generic biologics, because there can technically be no generic form of biologics. That is, the complex process of creating biologics, means that traditional definitions of bioequivalence used in the generic drug industry do not (or may not)...